Skip to content

US · ZURA · BIOTECHNOLOGY

Zura Bio Limited (ZURA) intrinsic value and stock valuation

$0.93as of 2026-11-21 · Mkt cap 535.79M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Zura Bio Limited DCF and intrinsic value

InvestorsCraft values ZURA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ZURA’s statements →

Zura Bio Limited Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Henderson, NV 89014 zurabio.com

How the business is doing

Fiscal 2021–2025, USD

Revenue
$0.00
20212025
Net income
-$-68.65M
20212025
Free cash flow
-$-64.93M
20212025
Total equity
$101.5M
20222025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-75.25M-$-55.19M-$-62.64M-$-27.16M-$-1.09M
Net income-$-68.65M-$-52.4M-$-60.36M-$-25.74M$8.42M
EPSd-$-729.08K-$-698.02K-$-1.83M-$-1.49M$488.1K
Operating cash flow-$-64.81M-$-28.08M-$-15.05M-$-1.2M-$-1.1M
Capital expenditure-$-110K-$-70K-$-8M-$-12M-$0.00
Free cash flow-$-64.93M-$-28.15M-$-23.05M-$-13.2M-$-1.1M
Total assets$114M$179.5M$100.8M$5.26M—
Total debt$0.00$0.00$0.00$7.76M—
Net debt-$-109.41M-$-176.5M-$-99.81M$6.19M—
Total equity$101.5M$160M$79.6M-$-22.06M—
Cash and short-term investments$109.4M$176.5M$99.8M$1.57M—
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$42.1M$24.4M$44M$23.7M$0.00
Selling, general and administrative expenses$33.2M$30.8M$18.6M$3.47M$1.09M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$75.3M$55.2M$62.6M$27.2M$1.09M
Cost and expenses$75.3M$55.2M$62.6M$27.2M$1.09M
Interest income$6.34M$8M$2.19M$0.00$20K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$50K$10K$0.00$0.00$0.00
Ebitda-$-68.6M-$-52.39M-$-60.56M-$-27.33M$8.42M
Operating income-$-75.25M-$-55.19M-$-62.64M-$-27.16M-$-1.09M
Total other income/expenses, net$6.6M$2.79M$2.08M-$-170K$9.51M
Income before tax-$-68.65M-$-52.4M-$-60.56M-$-27.33M$8.42M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-68.65M-$-52.4M-$-60.36M-$-25.74M$8.42M
Weighted average shares outstanding$94.2M$75.1M$33.1M$17.3M$17.3M
Weighted average diluted shares outstanding$94.2M$75.1M$33.1M$17.3M$17.3M
Balance sheet
2025202420232022
Cash and short-term investments$109.4M$176.5M$99.8M$1.57M
Net receivables$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Total current assets$112.3M$178.7M$100.8M$1.78M
Property, plant and equipment, net$130K$90K$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00
Total non-current assets$1.64M$790K$0.00$3.49M
Total assets$114M$179.5M$100.8M$5.26M
Accounts payable$1.28M$730K$2.75M$2.01M
Short-term debt$0.00$0.00$0.00$7.76M
Deferred revenue$0.00$0.00$0.00$0.00
Total current liabilities$12.4M$19.5M$20.3M$14.8M
Long-term debt$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$990K$12.5M
Capital lease obligations$0.00$0.00$0.00$0.00
Total liabilities$12.4M$19.5M$21.3M$27.3M
Common stock$10K$10K$0.00$0.00
Retained earnings-$-224.55M-$-155.9M-$-103.49M-$-32.06M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00
Total equity$101.5M$160M$79.6M-$-22.06M
Total investments$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$0.00$7.76M
Net debt-$-109.41M-$-176.5M-$-99.81M$6.19M
Cash flow statement
20252024202320222021
Net income-$-68.65M-$-52.4M-$-60.56M-$-27.33M$8.42M
Depreciation and amortization$50K$10K$0.00$0.00$0.00
Stock-based compensation$12.3M$16.8M$9.65M$330K$0.00
Change in working capital-$-3.63M$2.31M$5.12M$3.54M-$-240K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-2.16M$4.21M$0.00$290K$0.00
Net cash provided by operating activities-$-64.81M-$-28.08M-$-15.05M-$-1.2M-$-1.1M
Investments in property, plant and equipment-$-110K-$-70K-$-8M-$-12M$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-110K-$-5.08M-$-8M-$-12M-$-139.38M
Common stock issued$5.2M$60.8M$116.4M$0.00$140.8M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-2.16M$109.8M$121.3M$14.8M$141.2M
Net change in cash-$-67.09M$76.7M$98.2M$1.57M$730K
Cash at end of period$109.4M$176.5M$99.8M$1.57M$730K
Operating cash flow-$-64.81M-$-28.08M-$-15.05M-$-1.2M-$-1.1M
Capital expenditure-$-110K-$-70K-$-8M-$-12M-$0.00
Free cash flow-$-64.93M-$-28.15M-$-23.05M-$-13.2M-$-1.1M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Zura Bio Limited

        Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.

        CEO
        Sandeep C. Kulkarni
        Employees
        40
        Beta
        -0.04

        Explore

        Frequently asked questions

        What is the intrinsic value of Zura Bio Limited (ZURA)?

        InvestorsCraft does not currently publish an intrinsic value for ZURA. How the IC value is calculated.

        Is ZURA undervalued?

        InvestorsCraft does not publish an undervaluation signal for ZURA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.